Potential role of blood biomarkers in patients with fibromyalgia: a systematic review with meta-analysis
- PMID: 34966131
- DOI: 10.1097/j.pain.0000000000002510
Potential role of blood biomarkers in patients with fibromyalgia: a systematic review with meta-analysis
Abstract
Fibromyalgia (FM) is a complex chronic pain condition. Its symptoms are nonspecific, and to date, no objective test exists to confirm FM diagnosis. Potential objective measures include the circulating levels of blood biomarkers. This systematic review and meta-analysis aim to review studies assessing blood biomarkers' levels in patients with FM compared with healthy controls. We systematically searched the PubMed, MEDLINE, EMBASE, and PsycINFO databases. Fifty-four studies reporting the levels of biomarkers in blood in patients with FM were included. Data were extracted, and the methodological quality was assessed independently by 2 authors. The methodological quality of 9 studies (17%) was low. The results of most studies were not directly comparable given differences in methods and investigated target immune mediators. Thus, data from 40 studies only were meta-analyzed using a random-effects model. The meta-analysis showed that patients with FM had significantly lower levels of interleukin-1 β and higher levels of IL-6, IL-8, tumor necrosis factor-alpha, interferon gamma, C-reactive protein, and brain-derived neurotrophic factor compared with healthy controls. Nevertheless, this systematic literature review and meta-analysis could not support the notion that these blood biomarkers are specific biomarkers of FM. Our literature review, however, revealed that these same individual biomarkers may have the potential role of identifying underlying pathologies or other conditions that often coexist with FM. Future research is needed to evaluate the potential clinical value for these biomarkers while controlling for the various confounding variables.
Copyright © 2021 International Association for the Study of Pain.
References
-
- Aktürk S, Büyükavcı R. Evaluation of blood neutrophil-lymphocyte ratio and platelet distribution width as inflammatory markers in patients with fibromyalgia. Clin Rheumatol 2017;36:1885–9.
-
- Andrés-Rodríguez L, Borràs X, Feliu-Soler A, Pérez-Aranda A, Angarita-Osorio N, Moreno-Peral P, Montero-Marin J, García-Campayo J, Carvalho AF, Maes M. Peripheral immune aberrations in fibromyalgia: a systematic review, meta-analysis and meta-regression. Brain Behav Immun 2019;87:881–9.
-
- Andrés-Rodríguez L, Borràs X, Feliu-Soler A, Pérez-Aranda A, Rozadilla-Sacanell A, Arranz B, Montero-Marin J, García-Campayo J, Angarita-Osorio N, Maes M. Machine learning to understand the immune-inflammatory pathways in fibromyalgia. Int J Mol Sci 2019;20:4231.
-
- Ataoglu S, Ankarali H, Samanci R, Ozsahin M, Admis O. The relationship between serum leptin level and disease activity and inflammatory markers in fibromyalgia patients. North Clin Istanbul 2018;5:102.
-
- Aziz N. Measurement of circulating cytokines and immune-activation markers by multiplex technology in the clinical setting: what are we really measuring? For Immunopathol Dis Therap 2015;6:19–22.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
